AASLD: Hepatitis B (2009)

Zusammenfassung

AASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009 Anna S. F. Lok 1 and Brian J. McMahon 2 The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B are now posted online at www.aasld.org. This is the fourth ver- sion of this guideline; the last version was published in 2007. 1 The key changes in the 2009 version are new recom- mendations for first-line and second-line antiviral agents. Since the la

Kerninformationen

ose who remained viremic at week 72—received additional therapy with emtricitabine. Therefore, data on resis- tance to tenofovir monotherapy beyond 72 weeks can- not be determined from the two pivotal trials. The primary resistance mutation has not been determined. An alanine-to-threonine substituti...

l be receiv- ing cancer chemotherapy or long-term immunosuppres- sive therapy. Please refer to recommendations 1 and 39, and table 2. References 1. Lok ASF, McMahon BJ. Chronic hepatitis B. HEPATOLOGY2007;45:507- 539. Abbreviations: HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HIV, human im...

coni syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-1333. 5. Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivu- dine-experienced and lamivudine-naive patients. ...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen